Cargando…
The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients
PURPOSE: Anti-Xa peak level monitoring is recommended during LMWH treatment in renal impairment or obesity. The trough level has been proposed as marker for bleeding. We studied the influence of renal impairment and obesity on anti-Xa levels. METHODS: Peak and trough levels were collected during the...
Autores principales: | Mast, L., Peeters, M. Y. M., Söhne, M., Hackeng, C. M., Knibbe, C. A. J., van den Broek, M. P. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618299/ https://www.ncbi.nlm.nih.gov/pubmed/37707559 http://dx.doi.org/10.1007/s00228-023-03558-5 |
Ejemplares similares
-
Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury
por: Eck, R. J., et al.
Publicado: (2022) -
Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis
por: Buitenwerf, Edward, et al.
Publicado: (2015) -
Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
por: Vlot, E.A., et al.
Publicado: (2020) -
The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin
por: Sytema, Jelmer G., et al.
Publicado: (2023) -
Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels
por: Jaspers, Tessa C. C., et al.
Publicado: (2022)